Beta-secretase
BACE; β-Secretase
Beta-secretase (BACE) is a transmembrane aspartic proteinase responsible for cleaving the amyloid precursor protein (APP) to generate the soluble ectodomain sAPPbeta and its C-terminal fragment CTFbeta. BACE is a major target of Alzheimer's disease (AD) therapeutics. There are two forms of the enzyme: BACE1 and BACE2.
Deposition of amyloid-β protein (Aβ) to form neuritic plaques is the characteristic neuropathology of Alzheimer's disease (AD). Aβ is generated from APP by β- and γ-secretase cleavages. BACE1 is the β-secretase and its inhibition induces severe side effects, whereas its homolog BACE2 normally suppresses Aβ by cleaving APP/Aβ at the θ-site (Phe20) within the Aβ domain.
Beta-secretase Isoform Specific Products
All Product Categories
-
Beta-secretase Related Products (156)
Related Products (156)
-
Antibodies (1)
-
Beta-secretase Isoform Comparison
-
Umibecestat hydrochloride
0 ImagesCat. No.: HY-119689ACAS No.: 2365306-62-1Synonyms: CNP520 hydrochlorideUmibecestat hydrochloride (CNP520 hydrochloride) is a selective, orally active BACE inhibitor, with an IC50 of 11 nM for hBACE-1, 10 nM for mouse BACE-1, and 30 nM for hBACE-2. Umibecestat hydrochloride reduces β-Amyloid levels in the brain and cerebrospinal fluid, decreases β-amyloid plaque deposition, and inhibits plaque-associated neuroinflammation. Umibecestat hydrochloride is used in research related to Alzheimer's disease.
-
TPT-260
0 ImagesCat. No.: HY-13769CAS No.: 769856-81-7Synonyms: TPU260TPT-260 (TPU260), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (Kd = ~5 µM). TPT-260 increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease.
-
AZ-4217
0 ImagesCat. No.: HY-18112CAS No.: 1383846-83-0AZ-4217 is an inhibitor for β-site amyloid precursor protein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research.
-
Verubecestat tosylate
0 ImagesCat. No.: HY-16759BCAS No.: 1875153-95-9Synonyms: MK-8931 tosylateVerubecestat tosylate is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat tosylate effectively reduces Aβ40 and has the potential for Alzheimer's Disease.
-
LY2811376 (Standard)
0 ImagesCat. No.: HY-10472RCAS No.: 1194044-20-6LY2811376 (Standard) is the analytical standard of LY2811376 (HY-10472). This product is intended for research and analytical applications. LY2811376 is the first orally available non-peptidic β-secretase (BACE1) inhibitor with IC50 of 239 nM-249 nM, that acts to decrease Aβ secretion with EC50 of 300 nM, and demonstrates to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin.
-
Lanabecestat (Standard)
0 ImagesCat. No.: HY-100740RCAS No.: 1383982-64-6Synonyms: AZD3293 (Standard); LY3314814 (Standard)Lanabecestat (Standard) is the analytical standard of Lanabecestat. This product is intended for research and analytical applications. Lanabecestat (AZD3293) is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM. Lanabecestat is used for the research of Alzheimer's disease.
-
LX2343 (Standard)
0 ImagesCat. No.: HY-111383RCAS No.: 333745-53-2LX2343 (Standard) is the analytical standard of LX2343 (HY-111383). This product is intended for research and analytical applications. LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of Aβ clearance.
-
β-Secretase Inhibitor IV (Standard)
0 ImagesCat. No.: HY-10133RCAS No.: 797035-11-1β-Secretase Inhibitor IV (Standard) is the analytical standard of β-Secretase Inhibitor IV (HY-10133). This product is intended for research and analytical applications. β-Secretase Inhibitor IV is a potent, cell-active BACE-1 inhibitor with IC50s of 15.6 and 16.3nM under BACE-1 concentrations of 2 nM and 100 pM, respectively.
-
Eslicarbazepine (Standard)
0 ImagesCat. No.: HY-114703RCAS No.: 104746-04-5Synonyms: BIA 2-194 (Standard)Eslicarbazepine (Standard) is the analytical standard of Eslicarbazepine. This product is intended for research and analytical applications. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
-
SEVNLDAEFR
0 ImagesCat. No.: HY-P2714CAS No.: 186142-28-9SEVNLDAEFR is a substrate for BACE1.
-
SEW06622
0 ImagesCat. No.: HY-160037CAS No.: 261349-28-4SEW06622 is a BACE-1 inhibitor with an IC50 value of 6.3 μM and can be used in Alzheimer's disease research.
-
Aloeresin D (Standard)
0 ImagesCat. No.: HY-N2215RCAS No.: 105317-67-7Aloeresin D (Standard) is the analytical standard of Aloeresin D. This product is intended for research and analytical applications. Aloeresin D is a chromone glycoside isolated from Aloe vera, inhibits β-Secretase (BACE1) activity, with an IC50 of 39 μM.
-
PF-06663195
0 ImagesCat. No.: HY-138013CAS No.: 1621585-22-5PF-06663195 is a β-secretase (BACE1) inhibitor, with BACE1 CFA and BACE1 WCA IC50 values of 53 and 15 nM, respectively. PF-06663195 can be used for Alzheimer's disease research.
-
Verubecestat (Standard)
0 ImagesSynonyms: MK-8931 (Standard)Verubecestat (Standard) is the analytical standard of Verubecestat. This product is intended for research and analytical applications. Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease.
-
Elenbecestat (Standard)
0 ImagesCat. No.: HY-109055RCAS No.: 1388651-30-6Synonyms: E2609 (Standard)Elenbecestat (Standard) is the analytical standard of Elenbecestat (HY-109055). This product is intended for research and analytical applications. Elenbecestat (E2609) is a potent, orally bioavailable and BBB-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research.
-
BACE-IN-1
0 ImagesCat. No.: HY-U00287CAS No.: 1254166-60-3BACE-IN-1 (Compound 13) is a substituted lmidazo[1 ,2-a]pyridine derivative which can inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease.
